Development and implementation of ISAR, a new synthesis platform for radiopharmaceutical production by Frank, Christopher et al.
RESEARCH ARTICLE Open Access
Development and implementation of ISAR,
a new synthesis platform for
radiopharmaceutical production
Christopher Frank1*, Georg Winter1, Fredrik Rensei2, Victor Samper3, Allen F. Brooks4, Brian G. Hockley4,








University of Michigan, 2276
Medical Science Bldg I, SPC 5610,
Ann Arbor, MI 48109, USA
Full list of author information is
available at the end of the article
Abstract
Background: PET radiopharmaceutical development and the implementation of a
production method on a synthesis module is a complex and time-intensive task since
new synthesis methods must be adapted to the confines of the synthesis platform in use.
Commonly utilized single fluid bus architectures put multiple constraints on synthesis
planning and execution, while conventional microfluidic solutions are limited by
compatibility at the macro-to-micro interface. In this work we introduce the ISAR synthesis
platform and custom-tailored fluid paths leveraging up to 70 individually addressable
valves on a chip-based consumable. The ISAR synthesis platform replaces traditional
stopcock valve manifolds with a fluidic chip that integrates all fluid paths (tubing) and
valves into one consumable and enables channel routing without the single fluid bus
constraint. ISAR can scale between the macro- (10 mL), meso- (0.5 mL) and micro-
(≤0.05 mL) domain seamlessly, addressing the macro-to-micro interface challenge
and enabling custom tailored fluid circuits for a given application. In this paper we
demonstrate proof-of-concept by validating a single chip design to address the challenge
of synthesizing multiple batches of [13N]NH3 for clinical use throughout the workday.
Results: ISAR was installed at an academic PET Center and used to manufacture [13N]NH3
in > 96% radiochemical yield. Up to 9 batches were manufactured with a single
consumable chip having parallel paths without the need to open the hot-cell.
Quality control testing confirmed the ISAR-based [13N]NH3 met existing clinical
release specifications, and utility was demonstrated by imaging a rodent with
[13N]NH3 produced on ISAR.
Conclusions: ISAR represents a new paradigm in radiopharmaceutical
production. Through a new system architecture, ISAR integrates the principles of
microfluidics with the standard volumes and consumables established in PET
Centers all over the world. Proof-of-concept has been demonstrated through
validation of a chip design for the synthesis of [13N]NH3 suitable for clinical use.
Keywords: Microfluidics, Lab on a chip, Automation, [13N]ammonia, Myocardial
perfusion imaging
Background
Positron emission tomography (PET) is a functional molecular imaging technique that
utilizes bioactive molecules labeled with a positron-emitting radionuclide (radiophar-
maceuticals) to non-invasively quantify physiological and biochemical processes (for a
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general review of PET imaging, see: Ametamey et al. 2008). During the PET scan, sub-
jects receive a radiopharmaceutical dose and the scanner detects pairs of coincident
511 keV gamma photons emitted indirectly by the PET radionuclide. Data is then re-
constructed to generate the PET image. Several PET radiopharmaceuticals have been
approved for clinical use (Vavere and Scott 2017) and, reflecting this, millions of PET
scans occur worldwide every year (PET Imaging Market Summary Report 2018). The
short half-life of PET radionuclides (typically minutes – hours) mandates that radio-
pharmaceuticals are manufactured at a radiopharmacy facility that is in close proximity
to the clinical PET scanner(s) on a daily basis. The synthesis and delivery of PET radio-
pharmaceuticals for clinical use present some unique challenges including the need for
a manufacturing process that is rapid, reliable, automated and affordable so as to be
compatible with short-lived PET radionuclides, current Good Manufacturing Practice
(cGMP), radiation safety and healthcare economics. To accomplish daily dose produc-
tion, radiopharmaceuticals are typically manufactured using automated synthesis mod-
ules housed in lead-lined hot-cells (Thompson and Scott 2019).
Many traditional radiochemistry synthesis modules use a single fluid bus architecture
in conjunction with stopcock valve manifold(s), in which every fluid runs through parts
of the central pathway (Fig. 1). They are cassette-based systems that require a varying
degree of customer assembly, optimized for a single radionuclide and designed to pro-
duce one or a few large batches (e.g. tens to hundreds of GBq) of a given PET radio-
pharmaceutical for routine clinical use. For example, because [18F]fludeoxyglucose
([18F]FDG) is the most common PET radiopharmaceutical in clinical use and the half-
life of 18F (t1/2 = 110 min) is compatible with centralized production, many synthesis
modules have been designed for the express purpose of manufacturing [18F]FDG (Ame-
tamey et al. 2008; Yu 2006).
Therefore, the implementation of other syntheses requires subsequent adaptations of
the [18F]FDG baseline architecture (Yu 2006). However, the synthesis and utilization of
all PET radiopharmaceuticals does not necessarily fit this manufacturing paradigm. For
example, in developing markets there is a tendency to synthesize single patient doses as
needed, rather than large multidose batches. Alternatively, the use of short-lived PET
radionuclides (e.g. 15O (t1/2 = 2 min),
13N (t1/2 = 10 min),
11C (t1/2 = 20 min),
68Ga
(t1/2 = 68 min)) to label other radiopharmaceuticals necessitates de-centralized produc-
tion of different radiopharmaceuticals in batches suitable for 1–2 patients at a time on
Fig. 1 Cross section of single fluid bus consisting of a typical row of stopcock valves – the colored lines
represent different fluid paths that cross each other and therefore will contaminate each other with
residual liquid
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a continuous basis throughout the day (Wang et al. 2010; Elsinga 2012; Keng et al.
2012a; Rensch et al. 2013). Production of several batches on a single fluid path architec-
ture relies on replacing consumables multiple times per day, or rinsing procedures be-
tween production steps (to avoid cross contamination), which creates further expense
and/or complexity in validation of these cleaning processes (Haka et al. 2017).
There is a need for a more flexible radiopharmaceutical synthesis platform that is
compatible with different levels of radioactivity (single dose-on-demand production or
multidose batches) as well as a variety of radionuclides and/or radiopharmaceuticals,
and which can fit into the space confines of a typical radiopharmacy laboratory with
only one or two hot-cells. Ideally, it does not rely on cleaning procedures and aligns
with the state-of-the art approach of single-use disposables. To date, efforts in this dir-
ection have focused on development of microfluidic approaches for radiopharmaceuti-
cal manufacturing (Amaraesekera et al. 2013; Audrain 2007; Awasthi et al. 2014; Bejot
et al. 2010; Bouvet et al. 2011; Bouvet et al. 2012; Bouvet and Wuest 2013; Chen et al.
2014; Collier et al. 2010, 2017; De Leonardis et al. 2010, 2011; Gaja et al. 2012; Gillies
et al. 2006; Lu and Pike 2007; Lu and Pike 2010; Elizarov 2009; Elizarov et al. 2010;
Fortt and Gee 2013; Kealey et al. 2011; Keng et al. 2012b; Keng and van Dam 2015; Lee
et al. 2005; Liow et al. 2005; Liu et al. 2011; Liu et al. 2013; Lu et al. 2004, 2009, 2010;
Matesic et al. 2017; Miller 2009; Miller et al. 2010, 2011; Pascali et al. 2010, 2011, 2013;
Pascali and Salvadori 2016; Rensch et al. 2012, 2013; Selivanova et al. 2012; Simms
et al. 2012; Steel et al. 2007; Ungersboeck et al. 2011, 2012a, 2012b; Voccia et al. 2009;
Wang et al. 2010; Wang et al. 2019; Wester et al. 2009; Wheeler et al. 2010; Yokell
et al. 2012; Zeng et al. 2013), as well as purification/reformulation (Chao et al. 2017)
and quality control (QC) testing (Ha et al. 2017; Taggart et al. 2016; Ly et al. 2018).
While the benefits of microreactors for radiopharmaceutical synthesis have been well
documented in this multitude of literature precedent, and they have been used to pre-
pare radiopharmaceuticals for clinical use (Lebedev et al. 2013; Liang et al. 2014a,
2014b; Rensch et al. 2014), there are continuing challenges that have prevented them
from commercialization and really transitioning into widespread use to date (Chiu
et al. 2017). Notable exceptions in the PET space include ABTs BG75 (Awasthi et al.
2014) and the Advion Nanotek (Pascali et al. 2014), but both systems remain confined
to only a small number of laboratories around the world as of 2019.
The reasons for the slow uptake of microfluidic systems within the PET community
despite the well documented benefits are numerous and depend on the particular appli-
cation objective, but from the perspective of a clinical end user, include: I) system cost
(in our experience, some commercial microfluidic systems are almost double the cost
of standard radiopharmaceutical synthesis modules), II) the lack of availability of af-
fordable components due to dependence on chips, III) issues with the macro-to-micro
interface, or general incompatibility between microfluidic volumes (≤ 0.05 mL) and the
typical “large-scale” volumes used in cyclotrons and radiopharmaceutical dosing (≥
10 mL), and IV) a lack of improvement over existing technology.
To address a number of these issues, in this report we introduce ISAR1 (Fig. 2) as
well as the ISAR chip (Fig. 3), a readily available injection molded component that is
entirely manufactured out of cyclic olefin copolymer (COC) and integrates all reaction
1ISAR is the name of the synthesis module and not an acronym.
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vessels, fluid paths (tubing) and valves into one consumable, and enables direct point-
to-point channel routing. This work reduces to practice the lab-on-chip concepts that GE
have been developing in recent years (for example, see: Rensch et al. 2014, 2017, 2018).
Such a concept is analogous to multi-layered printed circuit boards in electronics. This
configuration eliminates a single fluid bus, thereby reducing challenges associated with
Fig. 2 ISAR unit (W x L x H 20 × 34 × 34 cm) with 70 luer connectors on top enabling the macro-to-
micro interface between the fluidic chip and standard laboratory items used in the production
of radiopharmaceuticals
Fig. 3 ISAR chip (W x L x H 10,4 × 10,4 × 0,6 cm) with 70 on-chip membrane valves hosting multiple parallel
fluid paths enabling point-to-point routing – the shown layout is designed for nine production runs
of [13N]NH3
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cross-contamination and the need for complex cleaning validation (Haka et al. 2017).
While the multi-layer fluid routing facilitates complex syntheses, the applicability to mul-
tiple independent productions has also been realized, and is the focus of this paper. The
ISAR system offers both parallel fluidics (Frank et al. 2018) and independent fluidics (this
work) (Fig. 4), potentially disruptive technologies that overcome the single fluid bus and
associated challenges at the macro-to-micro interface by marrying standard volumes, tech-
niques, and off-the-shelf components for radiopharmaceutical synthesis with the estab-
lished benefits of a microreactor setup.
Preliminary proof-of-concept was recently shown through the on chip synthesis of
two commonly used PET radiopharmaceuticals (Fig. 5). [18F] FDG (1) was produced
with an overall activity yield (AY) of ~ 65% (> 100 GBq) in less than 25 min and
[68Ga]PSMA-HBED-CC (2) was manufactured in a dual run scenario (two separate
runs from the same consumable) each resulting in ~ 44% AY (< 11.5 min synthesis
time) (Frank et al. 2018). On our development roadmap, these two steps confirmed I)
fundamental technical feasibility of ISAR, process efficiencies competitive to state-of-
the-art routine [18F] FDG production, II) reduced synthesis time, and III) capability of
multi-run architectures for e.g. two 68Ga syntheses from a single set of reagents. Fol-
lowing successful proof-of-concept demonstration, we next sought to install ISAR
under real-life conditions at a busy PET center and compare performance with existing
in-house standards for a challenging process. Concurrent with these efforts, we realized
that parallel processing is also well suited for multi-run schemes of simple production
processes, such as [13N]NH3 for myocardial perfusion imaging. We therefore selected
synthesis of [13N]NH3 for high resolution myocardial perfusion imaging (MPI) with
which to conduct the first field test of ISAR. Validation of the synthesis of [18F] FDG
and [68Ga] PSMA for clinical use are also ongoing and will be reported in due course.
Fig. 4 Illustration of the parallel fluidic architecture running on both sides of the same layer (doted lines on
the opposite side), thus enabling contamination free crossing of fluid paths
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Historically, assessments of myocardial perfusion are conducted with 82Rb because the
radionuclide is readily available from generators (Yoshinaga et al. 2010; Nakazato et al.
2013). However, owing to generator supply challenges and reduced imaging quality stem-
ming from the relatively high positron energy of 82Rb, there is motivation to conduct high
resolution myocardial perfusion imaging (MPI) with cyclotron-based [13N]NH3 instead
(Murthy et al. 2016). The transition to MPI with [13N]NH3 presents significant production
challenges to PET radiopharmaceutical manufacturers however. Specifically, the short
half-life of 13N (t1/2 = 10min) requires continuous production of high numbers of doses
throughout the day to meet busy imaging schedules. For particularly short-lived radionu-
clides, the regulations allow quality control (QC) testing to be conducted on an initial
sub-batch of the radiopharmaceutical (< 823 > Positron Emission Tomography Drugs for
Compounding, Investigational, and Research Uses, in USP 42-NF 37, 2018). Subsequent
sub-batches can then be manufactured and sent directly to the imaging suite in a given
period (usually 24 h) without additional QC testing. Despite the convenient sub-batch al-
lowance, the traditional Devarda’s alloy method used for routine synthesis of [13N]NH3 at
the University of Michigan PET Center requires new reagents and consumables for pro-
duction of each sub-batch (Scott 2012). This has inherent costs, operational complexity
(sub-batches need to be manufactured and purified from target impurities rapidly given
the short half-life; high numbers of batches are required per day (1–2 per patient); space
Fig. 5 The different Isotopes used, and radiopharmaceuticals produced with ISAR so far – (1)
[18F]fludeoxyglucose; (2) [68Ga]Ga-PSMA-HBED-CC; (3) [13N]NH3
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constraints limit how many batches can be set up in advance using a single hot-cell;
[13N]NH3 production needs to fit into a busy workflow where multiple lots of multiple
PET radiopharmaceuticals are already being prepared simultaneously), and undesirable
radiation exposure to workers who have to replace spent consumables throughout the day
that contain residual nitrogen-13 in spite of the short half-life. As such, we had a strong
interest in being able to prepare multiple 5.6–7.4 GBq sub-batches of [13N]NH3 with a
single consumable so that, after purification and transport to the imaging suite, it is pos-
sible to draw both rest (370MBq) and stress (740MBq) doses 20min apart from a single
batch. Leveraging the parallel fluidic architecture of our new chips as well as the small
dead volumes, in this paper we report installation of ISAR at the University of Michigan
PET Center and use of the system to produce up to 9 doses of [13N]NH3 (Fig. 5 (3)) using
a single consumable chip and set of reagents.
Methods
Safety and hazard considerations
Radioactivity and all hazardous chemicals were used by trained personnel under the
supervision of Environmental Health and Safety and the Radiation Policy Committee at
the University of Michigan.
Chip Design and manufacturing
The fluidic chip consumable integrates all reaction vessels, fluid paths and valves into
one consumable and is a readily available injection molded component that is entirely
manufactured out of cyclic olefin copolymer (COC). This material offers excellent re-
sistance against acids, bases, and solvents commonly used in the production of radio-
pharmaceuticals (e.g. acetonitrile and dimethyl sulfoxide). Three layers and a COC foil
are joined in a bonding process without the use of any adhesives or binders, reducing
material impurities and unwanted residuals (Fig. 6). To date over 1500 chips have been
Fig. 6 The different parts of the ISAR chip. The three different layers and the foil combined into a complete
chip during the bonding process
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produced with a scrap rate below 1%. Representative samples from each batch are
checked under the microscope and we have not observed any wear in the manufactur-
ing tools. Bond quality is currently conducted by visual inspection and destructive test-
ing of samples.
The COC foil forms the valves together with the valve layer that contains 70 mem-
brane valves. Those valves are connected through the routing layer towards reaction
structures on the chip, thus replacing the majority of tubing utilized in a conventional
consumable. At the same time, the available routing logic is increased by the high pack-
ing density of channels and structures on the chip. The valve array pattern is dictated
by injection molding considerations and the connection points follow an equal distance
distribution with two exceptions: two positioning pins and an additional area for fur-
ther connection points between the two reaction chambers. The fluid paths are then
designed to fit together with both patterns. The final chip dimensions are 104 × 104 × 6
mm (with a 3 mm 45° recess at one corner to help with correct orientation when used)
and valve spacing is 10.3 mm. Valves, as the critical structures, are specified to function
after > 100 actuation cycles and at 5 bar (72.5 psi) over pressure. To test this, > 250
valves were evaluated as shown in Table 1.
Access to off-the-shelf components such as solid phase extraction (SPE) cartridges
and fluid vials is maintained through 70 connection points on the connection layer,
that can serve as in-and/or outlets. The valve and connection layers are standardized
and injection molded parts. The routing layer can be manufactured by rapid prototyp-
ing (milling of a blank), or injection molding during commercialization ramp-up.
These are reliable techniques for manufacturing microfluidic chips (Attia et al. 2009;
Guckenberger et al. 2015), and have been successfully demonstrated for [18F] FDG
and [13N]NH3 ISAR chips. This enables manufacturing scalability from prototyping
across low rate initial production to cost competitive mass production of chips. In
addition, iterative process design is possible by making adaptive changes to the rout-
ing layer in the prototyping phase. It allows the production of custom-made chips in
the scale of a small series (10 to 500 copies) at acceptable cost. If the number of chips
required is high enough to justify it, the finalized design can then be transferred to in-
jection molding (Fig. 7).
The routing logic contains different reaction structures and channels customized to-
wards the process at hand. It can make use of two reaction chambers (~ 650 μL each)
and a variety of different fluidic structures, designed for mixing, metering of volumes,
and dilution. Everything can be either directly routed point-to-point (preventing cross
contamination or the need for cleaning validation), in a row, or in a combination of
both. External components such as standard SPE cartridges or vials can be routed ac-
cording to the same principle across I/Os of the connection layer. The channel diame-
ters can be selectively scaled from micro (< 50 μm) to macro (> 2 mm) depending on
the liquid volumes that need to be transferred and optimized (e.g. fluid volume, mass
Table 1 Valves Used in ISAR Chips
Entry Test Result n
1 N2 (2 bar) leakage < 10 μL/min > 250
2 Valve functional after > 100 cycles Pass > 250
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transfer, heat transfer, fluid viscosity and/or residual dead volume). The developer can
start with a sub-optimal design for first results and (re) iterate as required.
ISAR hardware
An ISAR unit is a compact, highly automated platform (Figs. 2 and 8), capable of pro-
ducing various radiopharmaceuticals using consumable chips that integrate all reaction
vessels, fluid paths (tubing) and valves into one consumable (Figs. 3, 6, 9 and 10). The
Fig. 7 Illustration of the chip design process. An existing chip layout is adopted to a new process or the
layout is created from scratch. Iterations of the layout are fabricated by milling the layout into a blank
routing layer, which later can be transferred to injection molding for mass production
Fig. 8 ISAR unit installed in hot-cell similar to the set up at the University of Michigan PET Center.
Installation at the University involved placing the ISAR module in a hot-cell, connecting it to mains power,
N2 gas (6 bar), a control laptop (ethernet) and the delivery line from the [
13N]NH3 target on the cyclotron.
Installation was completed in less than 1 h
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fluid paths are then designed to fit together with both patterns and with certain safety
and design considerations based on experience in mind From the point of view of rout-
ing fluids, the core functionality of the system is based on an actuator block, which en-
ables an individual binary on-chip valve control. The unit and consumable are brought
together by clamping the chip down by the top plate against the actuator block, simul-
taneously connecting the chip to the luer connectors integrated in the top plate and
putting the membrane valves in a normally closed position (Rensch et al. 2018). Each
valve membrane is pressed against its corresponding on-chip valve seat by a respective
electro-pneumatically actuated mechanical plunger (Fig. 9). The combination of
electro-pneumatics and the membrane valves allows for a precise, real-time control of
valves. Completion of each actuation is achieved within a reliable, defined time window
with actuation times of < 10ms (closed-open-closed cycle in < 30ms). This real-time
valve switching capability is in marked contrast to traditional stopcock valve manifolds,
which rely on rotational motion of valve drivers at actuation times often exceeding 1 s.
Fig. 9 Functionality of chip clamping and on-chip membrane valves. The top plate clamps the chip down
against the extended plungers. The plungers press the valve membranes inwards against the valve seats
and close therefore the valves are normally closed. In the same clamping motion, the luer connectors are
joined together with the connection points on the chip
Fig. 10 Simplified system boundaries for the nine-run [13N]NH3 chip. The radioactivity enters the chip
through the delivery line and is retained on one of nine SPE cartridges on separated fluid paths. The
transporting target fluid leaves the system again and flows into the waste. Water is used to flush the SPE
cartridge and also flows into the waste. Saline is used to elute and formulate the [13N]NH3 through one of
nine product lines
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Real-time valve control enables gas-pressure driven fluid transport at accuracies histor-
ically only achievable by syringe pumps (Rensch et al. 2017).
ISAR is designed to perform complete radiosyntheses on chip, as recently demon-
strated for [18F]FDG and [68Ga]PSMA-HBED-CC (see: Frank et al. 2018). As such, the
ISAR chip includes two reaction chambers, and heating of these chambers is performed
by four aluminum heating blocks. One above and below each reaction chamber. Active
cooling capabilities are provided by blowing N2 gas through the heating blocks, enab-
ling precise control and acceleration of cool-down ramps. Negative pressure can also
be applied to the chip by duty cycle control of a vacuum pump, which can also be
closed loop controlled, in combination with one of two installed pressure sensors, to a
pre-set pressure value within any structure on the chip. Compared with traditional syn-
thesizers, this allows a more precise application of vacuum, improving the overall
process control, e.g. for azeotropic drying procedures on-chip as demonstrated for
[18F]FDG (Frank et al. 2018).
To facilitate gas pressure driven fluid transport, the N2 gas source needed for the
clamping of the consumable and valve actuation is also further regulated by a mass flow
controller, capable of controlling both flow (up to 1000mL·min− 1) and pressure (up to
2 bar). Combined with metering structures and the precise actuating of valves
described, no syringe pumps are needed since fluids on the chip can be driven by over-
pressure. This allows highly efficient fluid recovery (Table 2), and helps to reduce the
cost, size and technical complexity of an ISAR unit. In addition, the available function-
ality for fluid routing and control is increased beyond what is achievable by some of the
largest (2x to 3x of ISAR unit size) stopcock valve and syringe pump-based synthesizers
currently available.
Radiosynthesis of [13N]NH3
To produce [13N]NH3, a custom chip layout was created utilizing the methods de-
scribed. It enables nine back-to-back productions without the need to reopen a hot-cell
(Fig. 8). Each production line on the chip is separated from one another, while still be-
ing fed by one delivery line and a single set of fluid-containers, e.g. water, saline, waste
(Fig. 10). The chip combined with the ISAR unit acts as a conductor between every-
thing entering and leaving the chip, while preventing cross contamination through
Table 2 Fluid recovery with ISAR
Liquid Target Achieved n
time volume accuracy time volume Standard deviation
min μL ±μL min μL ±μL
H2O 2 6000 200 3 6163 56 5
2 1500 200 4 1532 49 10
3 300 50 2 298 3 5
EtOH 2 1500 200 4 1512 69 10
2 400 50 3 378 22 6
3 100 50 1 101 4 10
MeCN 3 500 50 2 520 10 5
3 100 50 1 101 7 10
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downstream separation of each synthesis fluid path and maintenance of a single direc-
tion for fluid propagation. This is enabled by the chip architecture as described and is
not feasible on conventional stopcock valve-based synthesizers.
[13N]NH3 was prepared in target on a GE PETtrace cyclotron by irradiating aqueous
ethanol (5 mM) at 40 μA for 10–30 min, according to a published method (Wieland
et al. 1991). The resulting [13N]NH3 was then transferred to the ISAR unit through the
delivery line. Subsequently it was trapped on one of 9 parallel Waters CM-Light Sep-
Pak cartridges connected to the ISAR chip (Fig. 8). The cartridge was rinsed with sterile
water for injection, Ph. Eur. (2 mL), and afterwards [13N]NH3 was eluted from the cart-
ridge using 0.9% NaCl, Ph. Eur. (2 mL), through a 0.22 μm sterile filter (Millipore Millex
GS) into a sterile dose vial (Hollister-Stier). QC testing was completed as previously
described (Scott 2012). Processing of [13N]NH3 by ISAR took 5min after end-of-
bombardment.
Rodent PET imaging with [13N]NH3
Rodent PET imaging with [13N]NH3 was conducted in a female Sprague Dawley rat
(321 g) in accordance with the standards set by the Institutional Animal Care and Use
Committee at the University of Michigan. The animal was anesthetized (isoflurane),
intubated, and positioned in a Concorde MicroPET P4 scanner. Following a transmis-
sion scan, the animal was injected (i.v. via tail vein catheter as a bolus over 1 min) with
[13N]NH3 (10MBq) and the heart imaged for 30 min (6 × 5min frames).
Emission data were corrected for attenuation/scatter and reconstructed using the 3D
maximum a priori method. By using a summed image (Fig. 11), a region-of-interest
was drawn over the heart on multiple planes, and the corresponding volume of interest
applied to the full dynamic data set to generate a time-activity curve.
Results and discussion
The ISAR synthesis platform (Figs. 2 and 8) replaces the traditional stopcock valve
manifolds found on state-of-the-art radiopharmaceutical synthesis modules by means
Fig. 11 Summed transverse rodent image of [13N]NH3 (0–30 min after injection of the radiopharmaceutical)
showing excellent visualization of the heart and good heart-to background contrast and associated
time-radioactivity curve
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of a fluidic chip (Figs. 3 and 6) which integrates 70 membrane valves and fluid paths
(tubing) as well as 2 reaction chambers into one consumable, enabling channel routing
without traditional single fluid bus constraints. The chip can interface to SPE car-
tridges, different vial formats, sterile filters as well as inlet and outlet tubing employed
in radiopharmaceutical syntheses, ensuring compatibility at the macro-to-micro inter-
face. The prototype ISAR chips contain two reaction chambers as they were initially de-
veloped for complex tracer synthesis like [18F]FDG (Frank et al. 2018), and drying and
recovery of fluorine-18 in a reproducible way is challenging using alternative microflui-
dic approaches such as flow reactors, especially when standard vials and SPE cartridges
are used. We subsequently employed these prototype reactor-based chips to prepare
[68Ga]PSMA (Frank et al. 2018).
In combination with real-time valve control that enables gas-pressure driven fluid
transport at accuracies comparable to syringe pumps, ISAR combines the benefits of
both worlds, by downsizing where it is beneficial (e.g. reduced precursor consumption),
while maintaining established output volumes (e.g. 5–25mL), purification techniques
(SPE cartridges), and formulation methods. The flexibility offered by this technology
enables parallel fluidic processing. We realized that parallel processing is also well
suited for multi-run schemes of simple production processes (e.g. [13N]NH3), without
reuse of contaminated structures and complex cleaning validation (Haka et al. 2017).
While such could be possibly be accomplished with homemade valve manifolds, we are
unaware of any system capable of handling enough manifolds to offer 9 production
lines that are completely separate from each other and enable cGMP synthesis of mul-
tiple batches of [13N]NH3. Moreover, homemade systems are usually controlled by syr-
inge pumps, and not readily fed by single inputs for cyclotron target/water/saline input,
meaning footprints can be significantly larger. Contrastingly, ISAR is very compact,
uses a single set of reagents for 9 syntheses, and the speed of actuation is higher such
that there is no need for syringe pumps. As such, multiple ISAR units can easily be
installed in a single min-cell or hot-cell. The flexibility in chip design is an additional
advantage of ISAR. Small numbers of new chips can be rapidly accessed for evaluation
via rapid prototyping by, for example, 3D printing or milling (Fig. 7). This allows faster
implementation of established and new synthesis processes compared with stopcock
valve architectures, since the radiosynthesis no longer needs to be customized for the
consumable; instead the consumable can now be customized for the process.
With prototype systems built, it was next demonstrated that the ISAR system can be
installed at an academic PET Center and used for manufacturing of high quality
[13N]NH3. Installation was quick and simple (< 1 h) and 9 back-to-back batches of
[13N]NH3 were immediately produced without reopening the hot-cell or changing any
consumables (Table 3, entry 1). Additional runs with the same parameters were per-
formed (Table 3, entry 2) and confirmed that [13N]NH3 was obtained at > 96% radio-
chemical yield based on the input activity. To confirm suitability of [13N]NH3 prepared
on ISAR for clinical use, three additional sub-batches were prepared, and full QC test-
ing was completed (Table 3, entry 3; Table 4). All doses met or exceeded release cri-
teria for clinical application at the University of Michigan, including purity and sterility.
Yields were significantly higher than our existing method for producing [13N]NH3
using Devarda’s alloy (Table 3, entry 4), even accounting for differences in cyclotron
parameters (Scott 2012). Moreover, the ability to make 9 sub-batches of [13N]NH3 from
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a single consumable, compared with the existing Devarda’s alloy method that requires
replacement of consumables and reagents for every sub-batch (Scott 2012), improves
our throughput and streamlines daily production of [13N]NH3 for imaging multiple pa-
tients. These improvements in both yield and throughput represent dramatic enhance-
ments to the radiopharmaceutical process resulting from installation of ISAR at the
University of Michigan.
Although we only anticipate using a chip once for clinical production for the reasons
described above, we were next curious from a reliability perspective whether chips
could be re-used. Therefore, we investigated whether each fluid path, line and CM cart-
ridge could be used again by rinsing the three channels employed for making the ori-
ginal QC batches (Table 3, entry 3) with 10mL of sterile water for injection, Ph. Eur.
Rinsing was automated and performed without opening the hot-cell. Three additional
syntheses of [13N]NH3 were then performed using the same channels. There was no
impact on activity yield (Table 3, entry 5) and QC testing confirmed that these con-
secutive batches also met or exceeded all the necessary release criteria (data not
shown). Lastly, the ISAR system was also tested with higher levels of activity. The ir-
radiation time was increased to 30min at 40 μA, and the resulting activity was purified
and formulated without any anomalies to generate over 20 GBq of [13N]NH3 (Table 3,
entry 6).
In a final demonstration of the suitability of ISAR to produce radiopharmaceuticals
for in vivo PET imaging, the heart of a Sprague-Dawley rat was imaged with [13N]NH3
manufactured using ISAR (Fig. 11). The PET image demonstrated excellent
visualization of the heart and good heart-to-background contrast. A region-of-interest
Table 3 Activity yield of the [13N]NH3 Radiosyntheses
Entry Beam Activity Yield (GBq) n
1 40 μA for 10 min 7.0 ± 2.0 9
2 40 μA for 10 min 8.9 ± 0.3 8
3a 40 μA for 10 min 8.5 ± 0.7 3
4b 30 μA for 6 min 2.5 ± 0.2 3
5c 40 μA for 10 min 8.8 ± 0.1 3
6d 40 μA for 30 min 23.7 ± 0.9 2
a 1st run on chip; b traditional [13N]NH3 production using Devarda’s alloy (see: Scott 2012); c 2nd run on chip used in
entry 3; d Product was eluted with 8 mL of 0.9% NaCl, Ph. Eur. to simplify handling and QC analysis of the
concentrated dose
Table 4 QC Data for [13N]NH3 validation runs. All doses met or exceeded release criteria for clinical
application at the University of Michigan
QC Tests Specifications Lot 1 Lot 2 Lot 3
Visual Inspection Clear, colorless, no ppt Pass Pass Pass
Radiochemical-ID RRTa: 0.9–1.1 0.94 0.95 0.97
Radionuclidic-ID t1/2: 9.5–10.5 min 9.99 9.97 10.00
Filter integrity Bubble point ≥50 psi 53 61 62
Endotoxins ≤43.75 EU/mL < 2.00 < 2.00 < 2.00
Sterility No microbial growth Pass Pass Pass
pH value 4.5–7.5 5.0 5.0 5.0
RCP ≥90% > 99.9% > 99.9% > 99.9%
a RRT (Relative Retention Time) = tR [
13N]NH3/tR NH3 standard
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was established for the heart and used to generate the associated time-activity curve,
which was consistent with previous reports in the literature (Kim et al. 2015). Obtain-
ing the necessary U.S. regulatory approval to use [13N]NH3 manufactured with ISAR in
a clinical setting is underway.
Conclusion
ISAR represents a potential new paradigm in radiopharmaceutical production capitaliz-
ing on decades of synthesizer technology development. Through a new system architec-
ture, ISAR integrates the principles of microfluidics with the standard volumes and
consumables established in PET Centers all over the world. A parallel fluidic strategy
offers a promising approach for the automated production of radiopharmaceuticals and
has been demonstrated for [13N]NH3, leveraging the ability to create multiple separated
fluid paths on a single chip to its full potential. Validation of ISAR for production of
other PET radiopharmaceuticals is ongoing. Straightforward compliance with cGMP is
possible because of the consumable approach, since the ISAR chips interface with
established reagent kits and SPE cartridges, as well as existing aseptic techniques.
Abbreviations
[18F]FDG: [18F]fludeoxyglucose; AY: Activity yield; Bq: Becquerels; cGMP: Current good manufacturing practice;
COC: Cyclic olefin copolymer; MPI: Myocardial perfusion imaging; PET: Positron emission tomography; QC: Quality
control; RCP: Radiochemical purity; SPE: Solid-phase extraction
Acknowledgments
The authors thank Janna Arteaga, Jenelle Stauff and Phillip Sherman for assistance with the rodent PET scan, and all
project members involved during ISAR development at former GE Global Research (Munich, Germany).
Authors’ contributions
CF, GW, CR and PJHS conceived and designed experiments; CF, GW, FR, VS, CR designed and assembled ISAR; GW,
AFB and BDH conducted [13N]NH3 manufacturing and quality control testing; BDH and BGH provided quality
assurance and regulatory oversight; AFB and PJHS analyzed PET images; all authors analyzed data and wrote the
manuscript. All authors read and approved the final manuscript.
Funding
Financial support from the Bundesministerium für Bildung und Forschung (German Federal Ministry of Education and
Research) is gratefully acknowledged.
Availability of data and materials
The datasets generated during and/or analyzed during the current study are available from the corresponding author
on reasonable request.





CF, GW, FR, VS, and CR are employees of General Electric.
Author details
1GE Healthcare, Oskar-Schlemmer-Str. 11, 80807 Munich, Germany. 2GE Healthcare, Uppsala, Sweden. 3GE Additive,
Garching near Munich, Germany. 4Department of Radiology, University of Michigan, 2276 Medical Science Bldg I, SPC
5610, Ann Arbor, MI 48109, USA.
Received: 18 July 2019 Accepted: 30 August 2019
References
Amaraesekera B, Marchis PD, Bobinski KP, Radu CG, Czernin J, Barrio JR, van Dam RM. High-pressure, compact, modular
radiosynthesizer for production of positron emitting biomarkers. Appl Radiat Isot. 2013;78:88–101.
Ametamey SM, Honer M, Schubiger PA. Molecular imaging with PET. Chem Rev. 2008;108:1501–16.
Attia UM, Marson S, Alcock JR. Micro-injection moulding of polymer microfluidic devices. Microfluid Nanofluid. 2009;7:1–28.
Frank et al. EJNMMI Radiopharmacy and Chemistry            (2019) 4:24 Page 15 of 18
Audrain H. Positron emission tomography (PET) and microfluidic devices: a breakthrough on the microscale? Angew Chem
Int Ed. 2007;46:1772–5.
Awasthi V, Watson J, Gali H, Matlock G, McFarland A, Bailey J, Anzellotti A. A "dose on demand" biomarker generator for
automated production of [18F]F− and [18F]FDG. Appl Radiat Isot. 2014;89:167–75.
Bejot R, Kersemans V, Kelly C, Carroll L, King RC, Gouverneur V, Elizarov AM, Ball C, Zhang J, Miraghaie R, Kolb HC, Smart S, Hill
S. Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F] FMISO as hypoxia-selective tracer for PET. Nucl Med
Biol. 2010;37:565–75.
Bouvet V, Wuest M, Tam PH, Wang M, Wuest F. Microfluidic technology: an economical and versatile approach for the
synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET). Bioorg Med Chem Lett. 2012;22:2291–5.
Bouvet VR, Wuest F. Application of [18F] FDG in radiolabeling reactions using microfluidic technology. Lab Chip. 2013;13:
4290–4.
Bouvet VR, Wuest M, Wiebe LI, Wuest F. Synthesis of hypoxia imaging agent 1-(5-deoxy-5-fluoro-α-D-arabinofuranosyl)-2-
nitroimidazole using microfluidic technology. Nucl Med Biol. 2011;38:235–45.
Chao PH, Collins J, Argus JP, Tseng W-Y, Lee JT, van Dam RM. Automatic concentration and reformulation of PET tracers via
microfluidic membrane distillation. Lab Chip. 2017;17:1802–16.
Chen S, Javed MR, Kim HK, Lei J, Lazari M, Shah GJ, van Dam RM, Keng PY, Kim CJ. Radiolabelling diverse positron emission
tomography (PET) tracers using a single digital microfluidic reactor chip. Lab Chip. 2014;14:902–10.
Chiu DT, DeMello AJ, Carlo DD, Doyle PS, Hansen C, Maceiczyk RM, Wootton RCR. Small but perfectly formed? Successes,
challenges, and opportunities for microfluidics in the chemical and biological cciences. Chem. 2017;2:201–23.
Collier T, Akula M, Kabalka G. Microfluidic synthesis of [18F] FMISO. J Nucl Med. 2010;51(Suppl. 2):1462.
Collier TL, Liang SH, Mann JJ, Vasdev N, Kumar JSD. Microfluidic radiosynthesis of [18F] FEMPT, a high affinity PET radiotracer
for imaging serotonin receptors. Beilstein J Org Chem. 2017;13:2922–7.
De Leonardis F, Pascali G, Salvadori PA, Watts P, Pamme N. Microfluidic modules for [18F−] activation - towards an integrated
modular lab on a chip for PET radiotracer synthesis. Proc MicroTAS. 2010:1604–6.
De Leonardis F, Pascali G, Salvadori PA, Watts P, Pamme N. On-chip pre-concentration and complexation of [18F]
fluoride ions via regenerable anion exchange particles for radiochemical synthesis of positron emission
tomography tracers. J Chromatogr A. 2011;1218:4714–9.
Elizarov AM. Microreactors for radiopharmaceutical synthesis. Lab Chip. 2009;9:1326–33.
Elizarov AM, van Dam RM, Shin YS, Kolb HC, Padgett HC, Stout D, Shu J, Huang J, Daridon A, Heath JR. Design and
optimization of coin-shaped microreactor chips for PET radiopharmaceutical synthesis. J Nucl Med. 2010;51:282–7.
Elsinga PH. Present and future of PET radiopharmaceuticals. Nucl Med Rev. 2012;15:C13–6.
Fortt R, Gee A. Microfluidics: a golden opportunity for positron emission tomography? Future Med Chem. 2013;5:241–4.
Frank C, Winter G, Rensei F, Sampler V, Bartenstein P, Brooks A, Hockley B, Henderson B, Lindner S, Rensch C, Scott P.
Enhancing radiotracer development: channel routing on ISAR without single fluid bus constraint. J Nucl Med. 2018;
59(Suppl. 1):671.
Gaja V, Gómez-Vallejo V, Cuadrado-Tejedor M, Borrell JI, Llop J. Synthesis of 13N-labelled radiotracers by using microfluidic
technology. J Label Compd Radiopharm. 2012;55:332–8.
Gillies JM, Prenant C, Chimon GN, Smethurst GJ, Perrie W, Hamblett I, Dekker B, Zweit J. Microfluidic reactor for the
radiosynthesis of PET radiotracers. Appl Radiat Isot. 2006;64:325–32.
Guckenberger DJ, de Groot TE, Wan AMD, Beebe DJ, Young EWK. Micromilling: a method for ultra-rapid prototyping of
plastic microfluidic devices. Lab Chip. 2015;15:2364–78.
Ha NS, Sadeghi S, Van Dam RN. Recent progress toward microfluidic quality control testing of radiopharmaceuticals.
Micromachines. 2017;8:337.
Haka M, Walsh J, Webster E. P450: cleaning validation concepts for commercial radiopharmaceutical manufacturing. J Label
Compd Radiopharm. 2017;60(Suppl 1):S632.
Kealey S, Plisson C, Collier TL, Long NJ, Husbands SM, Martarello L, Gee AD. Microfluidic reactions using [11C] carbon
monoxide solutions for the synthesis of a positron emission tomography radiotracer. Org Biomol Chem. 2011;9:3313–9.
Keng PY, Chen S, Ding H, Sadeghi S, Shah GJ, Dooraghi A, Phelps ME, Satyamurthy N, Chatziioannou AF, Kim CJ, van Dam
RM. Micro-chemical synthesis of molecular probes on an electronic microfluidic device. Proc Natl Acad Sci U S A. 2012b;
109:690–5.
Keng PY, Esterby M, van Dam RM. Emerging technologies for decentralized production of PET tracers. In: Hsieh C-H, editor.
Positron Emission Tomography – Current Clinical and Research Applications. Rijeka: InTech; 2012a, Ch. 6. p. 153–82.
Keng PY, van Dam RM. Digital microfluidics: a new paradigm for radiochemistry. Mol Imaging. 2015;14:13–4.
Kim DY, Kim HS, Reder S, Zheng JH, Herz M, Higuchi T, Pyo AY, Bom HS, Schwaiger M, Min JJ. Comparison of 18F-labeled
fluoroalkylphosphonium cations with 13N-NH3 for PET myocardial perfusion imaging. J Nucl Med. 2015;56:1581–6.
Lebedev A, Miraghaie R, Kotta K, Ball CE, Zhang J, Buchsbaum MS, Kolb HC, Elizarov A. Batch-reactor microfluidic device: first
human use of a microfluidically produced PET radiotracer. Lab Chip. 2013;13:136–45.
Lee CC, Sui G, Elizarov A, Shu CJ, Shin YS, Dooley AN, Huang J, Daridon A, Wyatt P, Stout D, Kolb HC, Witte ON, Satyamurthy
N, Heath JR, Phelps ME, Quake SR, Tseng HR. Multistep synthesis of a radiolabeled imaging probe using integrated
microfluidics. Science. 2005;310:1793–6.
Liang SH, Yokell DL, Jackson RN, Rice PA, Callahan R, Johnson KA, Alagille D, Tamagnan G, Collier TL, Vasdev N.
Microfluidic continuous-flow radiosynthesis of [18F] FPEB suitable for human PET imaging. Med Chem Commun.
2014a;5:432–5.
Liang SH, Yokell DL, Normandin MD, Rice PA, Jackson RN, Shoup TM, Brady TJ, El Fakhri G, Collier TL, Vasdev N. First human
use of a radiopharmaceutical prepared by continuous-flow microfluidic radiofluorination: proof of concept with the tau
imaging agent [18F]T807. Mol Imaging. 2014b;13. https://doi.org/10.2310/7290.2014.00025.
Liow E, O’Brien A, Luthra S, Brady F, Steel C. Preliminary studies of conducting high level production radiosyntheses using
microfluidic devices. J Label Compd Radiopharm. 2005;48:28.
Liu K, Lepin EJ, Wang MW, Guo F, Lin WY, Chen YC, Sirk SJ, Olma S, Phelps ME, Zhao XZ, Tseng HR, Michael van Dam R, Wu
AM, Shen CK. Microfluidic-based 18F-labeling of biomolecules for immuno-positron emission tomography. Mol Imaging.
2011;10:168–76.
Frank et al. EJNMMI Radiopharmacy and Chemistry            (2019) 4:24 Page 16 of 18
Liu Y, Tian M, Zhang H. Microfluidics for synthesis of peptide-based PET tracers. Biomed Res Int. 2013;2013, 839683.
Lu S, Chun JH, Pike VW. Fluorine-18 chemistry in micro-reactors. J Labelled Comp Radiopharm. 2010;53:234–8.
Lu S, Giamis AM, Pike VW. Synthesis of [18F] fallypride in a micro-reactor: rapid optimization and multiple-production in small
doses for micro-PET studies. Curr Radiopharm. 2009;2:49–55.
Lu S, Pike VW. Synthesis of [18F] xenon difluoride as a radiolabeling reagent from [18F] fluoride ion in a micro-reactor and at
production scale. J Fluor Chem. 2010;131:1032–8.
Lu SY, Pike VW. Micro-reactors for PET tracer labeling. Ernst Schering Res Found Workshop. 2007;62(PET Chemistry):271–87.
Lu SY, Watts P, Chin FT, Hong J, Musachio JL, Briard E, Pike VW. Syntheses of 11C- and 18F-labeled carboxylic esters within a
hydrodynamically-driven micro-reactor. Lab Chip. 2004;4:523–5.
Ly J, Ha NS, Cheung S, van Dam RM. Toward miniaturized analysis of chemical identity and purity of radiopharmaceuticals via
microchip electrophoresis. Anal Bioanal Chem. 2018;410:2423–36.
Matesic L, Kallinen A, Greguric I, Pascali G. Dose-on-demand production of diverse 18F-radiotracers for preclinical applications
using a continuous flow microfluidic system. Nucl Med Biol. 2017;52:24–31.
Miller PW. Radiolabelling with short-lived PET (positron emission tomography) isotopes using microfluidic reactors. J Chem
Technol Biotechnol. 2009;84:309–15.
Miller PW, Audrain H, Bender D, deMello AJ, Gee AD, Long NJ, Vilar R. Rapid carbon-11 radiolabelling for PET using
microfluidics. Chem A Eur J. 2011;17:460–3.
Miller PW, de Mello AJ, Gee AD. Application of microfluidics to the ultra-rapid preparation of fluorine-18 labelled compounds.
Curr Radiopharm. 2010;3:254–62.
Murthy VL, Leuschner M, Scott PJH, Doughty M, Weinberg RL, Ficaro EP, Corbett JR. Abstracts of original contributions
ASNC2016. Abstract 302-05: initial validation of a highly automated superconducting mini-cyclotron for decentralized
production of 13N-ammonia. J Nucl Cardiol. 2016;23:899–937.
Nakazato R, Berman DS, Alexanderson E, Slomka P. Myocardial perfusion imaging with PET. Imaging Med. 2013;5:35–46.
Pascali G, Berton A, DeSimone M, Wyatt N, Matesic L, Greguric I, Salvadori PA. Hardware and software modifications on the
Advion NanoTek microfluidic platform to extend flexibility for radiochemical synthesis. Appl Radiat Isot. 2014;84:40–7.
Pascali G, Mazzone G, Saccomanni G, Manera C, Salvadori PA. Microfluidic approach for fast labeling optimization and dose-
on-demand implementation. Nucl Med Biol. 2010;37:547–55.
Pascali G, Nannavecchia G, Pitzianti S, Salvadori PA. Dose-on-demand of diverse 18F-fluorocholine derivatives through a two-
step microfluidic approach. Nucl Med Biol. 2011;38:637–44.
Pascali G, Salvadori PA. Opportunities and challenges in the utilization of microfluidic technologies to the production of
radiopharmaceuticals. Chim Oggi Chem Today. 2016;34:28–32.
Pascali G, Watts P, Salvadori PA. Microfluidics in radiopharmaceutical chemistry. Nucl Med Biol. 2013;40:776–87.
PET Imaging Market Summary Report 2018. Available from: https://imvinfo.com/product/pet-imaging-market-summary-
report-2018/; Accessed 4 July 2019.
<823> Positron Emission Tomography Drugs for Compounding, Investigational, and Research Uses, in United States
Pharmacopeia / National Formulary (USP 42-NF 37), The United States Pharmacopeia Convention, Rockville, 2018, Ch. 823
pp 322-331.
Rensch C, Jackson A, Lindner S, Salvamoser R, Samper V, Riese S, Bartenstein P, Wängler C, Wängler B. Microfluidics: a
groundbreaking technology for PET tracer production? Molecules. 2013;18:7930–56.
Rensch C, Lindner S, Salvamoser R, Leidner S, Böld C, Samper V, Taylor D, Baller M, Riese S, Bartenstein P, Wängler C, Wängler
B. A solvent resistant lab-on-chip platform for radiochemistry applications. Lab Chip. 2014;14:2556–64.
Rensch C, Salvamoser R, Lang P, Samper V, Winter G, Frank C, Hienzsch A, Hesse R, Müller M, Hoepping A. Gas pressure
driven fluid transport for radiochemistry on-chip. J Label Compd Radiopharm. 2017;60(Suppl. 1):O 064.
Rensch C, Samper V, Salvamoser R. Compact valve array with actuation system. US Pat. 2018;20180078937:A1.
Rensch C, Waengler B, Yaroshenko A, Samper V, Baller M, Heumesser N, Ulin J, Riese S, Reischl G. Microfluidic reactor
geometries for radiolysis reduction in radiopharmaceuticals. Appl Radiat Isot. 2012;70:1691–7.
Scott PJH. Synthesis of [13N] Ammonia ([13N]NH3). In: PJH S, Hockley BG, editors. Radiochemical Syntheses Volume 1:
Radiopharmaceuticals for PET Imaging. Hoboken: Wiley; 2012;Ch. 31. p. 315–20.
Selivanova SV, Mu L, Ungersboeck J, Stellfeld T, Ametamey SM, Schibli R, Wadsak W. Single-step radiofluorination of peptides
using continuous flow microreactor. Org Biomol Chem. 2012;10:3871–4.
Simms RW, Causey PW, Weaver DM, Sundararajan C, Stephenson KA, Valliant JF. Preparation of technetium-99m bifunctional
chelate complexes using a microfluidic reactor: a comparative study with conventional and microwave labeling
methods. J Label Compd Radiopharm. 2012;55:18–22.
Steel CJ, O’Brien AT, Luthra SK, Brady F. Automated PET radiosyntheses using microfluidic devices. J Label Compd
Radiopharm. 2007;50:308–11.
Taggart MP, Tarn MD, Esfahani MM, Schofield DM, Brown NJ, Archibald SJ, Deakin T, Pamme N, Thompson LF. Development
of radiodetection systems towards miniaturised quality control of PET and SPECT radiopharmaceuticals. Lab Chip. 2016;
16:1605–16.
Thompson S, Scott PJH. Equipment and instrumentation for radiopharmaceutical chemistry. In: Lewis JS, Windhorst
AD, Zeglis BM, editors. Radiopharmaceutical Chemistry. New York: Springer; 2019. p. 481–99.
Ungersboeck J, Philippe C, Haeusler D, Mitterhauser M, Lanzenberger R, Dudczak R, Wadsak W. Optimization of [11C]DASB-
synthesis: vessel-based and flow-through microreactor methods. Appl Radiat Isot. 2012a;70:2615–20.
Ungersboeck J, Philippe C, Mien LK, Haeusler D, Shanab K, Lanzenberger R, Spreitzer H, Keppler BK, Dudczak R, Kletter K,
Mitterhauser M, Wadsak W. Microfluidic preparation of [18F]FE@SUPPY and [18F]FE@SUPPY:2--comparison with
conventional radiosyntheses. Nucl Med Biol. 2011;38:427–34.
Ungersboeck J, Richter S, Collier L, Mitterhauser M, Karanikas G, Lanzenberger R, Dudczak R, Wadsak W. Radiolabeling of [18F]
altanserin - a microfluidic approach. Nucl Med Biol. 2012b;39:1087–92.
Vavere AL, Scott PJH. Clinical applications of small-molecule PET radiotracers: Current progress and future outlook. Semin
Nucl Med. 2017;47:429–53.
Voccia S, Morelle JL, Aerts J, Lemaire C, Luxen A, Phillipart G. Mini-fluidic chip for the total synthesis of PET tracers. J Label
Compd Radiopharm. 2009;52(Suppl):S11.
Frank et al. EJNMMI Radiopharmacy and Chemistry            (2019) 4:24 Page 17 of 18
Wang J, Chao PH, van Dam RM. Ultra-compact, automated microdroplet radiosynthesizer. Lab Chip. 2019. https://doi.org/10.
1039/c9lc00438f.
Wang M-W, Lin W-Y, Liu K, Masterman-Smith M, Shen CK-F. Microfluidics for positron emission tomography (PET) imaging
probe development. Mol Imaging. 2010;9:175–91.
Wester HJ, Schoultz BW, Hultsch C, Henriksen G. Fast and repetitive in-capillary production of [18F]FDG. Eur J Nucl Med Mol
Imaging. 2009;36:653–8.
Wheeler TD, Zeng D, Desai AV, Önal B, Reichert DE, Kenis PJ. Microfluidic labeling of biomolecules with radiometals for use in
nuclear medicine. Lab Chip. 2010;10:3387–96.
Wieland B, Bida G, Padgett H, Hendry G, Zippi E, Kabalka G, Morelle J-L, Verbruggen R, Ghyoot M. In target production of 13N-
ammonia via proton irradiation of aqueous ethanol and acetic acid mixtures. Appl Radiat Isot. 1991;42:1095–8.
Yokell DL, Leece AK, Lebedev A, Miraghaie R, Ball CE, Zhang J, Kolb H, Elizarov A, Mahmood U. Microfluidic single vessel
production of hypoxia tracer 1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole ([18F]-FMISO). Appl Radiat Isot. 2012;
70:2313–6.
Yoshinaga K, Klein R, Tamaki N. Generator-produced rubidium-82 positron emission tomography myocardial perfusion
imaging: from basic aspects to clinical applications. J Cardiol. 2010;55:163–73.
Yu S. Review of 18F-FDG synthesis and quality control. Biomed Imaging Interv J. 2006;2:e57.
Zeng D, Desai AV, Ranganathan D, Wheeler TD, Kenis PJ, Reichert DE. Microfluidic radiolabeling of biomolecules with PET
radiometals. Nucl Med Biol. 2013;40:42–51.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Frank et al. EJNMMI Radiopharmacy and Chemistry            (2019) 4:24 Page 18 of 18
